Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03363776 · ClinicalTrials.gov registry record · Phase 1
An Investigational Immuno-Therapy Study of Experimental Medication BMS-986277 Given Alone and in Combination With Nivolumab in Epithelial Cancers
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Terminated
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT03363776 is a Phase 1 study that was terminated before completion, run by Bristol-Myers Squibb. The registered enrollment target is 10 participants.
The verdict
NCT03363776, a Phase 1 study, was terminated before completion, sponsored by Bristol-Myers Squibb.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate experimental medication BMS-986277 given alone and in combination with Nivolumab in patients with epithelial cancers.
Interventions
- BIOLOGICAL Nivolumab
- BIOLOGICAL BMS-986277
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2017-12-06 |
| Est. Completion | 2019-11-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03363776
The ClinicalTrials.gov registry entry for NCT03363776 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Nivolumab is the first listed.
NCT03363776 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03363776 about?
NCT03363776 is a clinical study titled "An Investigational Immuno-Therapy Study of Experimental Medication BMS-986277 Given Alone and in Combination With Nivolumab in Epithelial Cancers". The purpose of this study is to investigate experimental medication BMS-986277 given alone and in combination with Nivolumab in patients with epithelial cancers.
What is the current status of trial NCT03363776?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2017-12-06. Estimated completion is 2019-11-22.
What interventions are being tested in trial NCT03363776?
The interventions under investigation include: Nivolumab (BIOLOGICAL), BMS-986277 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03363776?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.